DEF 14A: GT Biopharma Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

GT Biopharma will hold its annual stockholders meeting virtually on June 25, 2024, to vote on the election of directors, ratification of independent accountants, and executive compensation.

Summary

• GT Biopharma, Inc. will hold its Annual Meeting of Stockholders on June 25, 2024, at 11:00 A.M. Pacific time, conducted virtually via live webcast.
• Stockholders of record as of April 26, 2024, are entitled to notice and to vote at the meeting.
• The meeting will address the election of four directors, ratification of Weinberg & Company, P.A. as the company's independent accountants for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation.
• The Board of Directors recommends voting FOR the election of the director nominees, FOR the ratification of Weinberg & Company, P.A., and FOR the endorsement of executive compensation.
• The proxy materials, including the proxy statement and the Annual Report on Form 10-K for the year ended December 31, 2023, are available online at www.proxyvote.com and on the Investors section of the company's website.
• As of the record date, April 26, 2024, there were 1,380,633 shares of common stock outstanding and entitled to vote.
• A majority of the outstanding shares, or 690,317 shares, constitutes a quorum for the meeting.
• The Board of Directors has fixed the number of directors at five, with one current vacancy.
• The company's executive compensation program reflects a variable pay-for-performance philosophy.
• The maximum number of shares of common stock that may be issued pursuant to awards granted under the 2022 Plan is 5,000,000.

Sentiment

Score: 5

Explanation: The document is neutral in tone, providing factual information about the upcoming annual meeting and related proposals. The financial performance is mixed, with a net loss but also a decrease in that loss compared to previous years.

Positives

• The company is providing stockholders with multiple methods to vote, including online, telephone, and mail.
• The Audit Committee has determined that Mr. Casamento is an audit committee financial expert, as defined in Item 407(d)(5) of Regulation S-K.
• The company has adopted a Board Diversity Policy with respect to its efforts in cultivating a board of directors with diversity, including diversity of expertise, experience, background and gender.

Negatives

• The company experienced a net loss of $7,597,000 in 2023.
• The value of an investment of $100 in the company's common stock on the last trading day of 2020 decreased to $3.54 by the end of 2023.
• There is currently one vacancy on the Board of Directors.

Risks

• The company's future performance is subject to various risks, including those related to liquidity, operations, and cybersecurity.
• The outcome of the advisory vote on executive compensation could influence future compensation arrangements.
• Failure to maintain a quorum at the Annual Meeting could necessitate adjournment to a later date.

Future Outlook

The company's Board of Directors will continue to review potential candidates to fill the current vacancy on the Board.

Management Comments

• Mr. Breen serves as our Executive Chairman of the Board and Interim Chief Executive Officer.
• We believe that combining the role of Chairman of the Board and Chief Executive Officer is appropriate to provide the authority necessary for Mr. Breen to effectively lead our company through its current phase of growth.

Industry Context

This proxy statement is a standard document for publicly traded companies, outlining the matters to be voted on at the annual meeting and providing information about the company's directors, executive compensation, and corporate governance practices.

Comparison to Industry Standards

• The executive compensation structure, including salary, bonus, stock awards, and option awards, is typical for companies in the biotechnology industry.
• The use of an independent compensation consultant, Pearl Meyer & Partners, LLC, is a common practice among publicly traded companies to ensure that executive compensation is aligned with market standards.
• The company's Board Diversity Policy is in line with Nasdaq Rule 5606, which requires companies to disclose information about the gender and demographic diversity of their directors.

Stakeholder Impact

• The outcome of the votes on the proposals will impact the composition of the Board of Directors, the selection of the company's independent accountants, and the company's executive compensation practices.
• The company's financial performance and corporate governance practices are of interest to shareholders, employees, and other stakeholders.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary results at the Annual Meeting and report final results on a Current Report on Form 8-K filed with the SEC.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Independent Accountants, Director Election, GT Biopharma